Anurag Kumar
CFO
Get their honest, personalized take on your startup.
Sign in to pitch Anurag →At a glance
- Full Name
- Anurag Kumar
- Title
- Chief Financial Officer (CFO)
- Firm
- Jacob Ballas Capital India Private Limited
- Firm Type
- Private equity advisory / growth-equity investment firm (NBFC). *(Note: the stub described "Angel Investors / Seed Round," but Jacob Ballas is an institutional growth-equity firm, not an angel network.)*
- Investment Stage
- Growth equity / late-stage (commonly described as Series B and beyond)
- Check Size
- ~US$10–50 million per investment (firm-level)
- Target Company Profile
- Established, profitable or scaling private companies seeking growth capital, typically with a 3–5 year horizon and exit via strategic sale or IPO
- Sector Focus
- Healthcare & diagnostics, financial services & fintech, consumer/retail, media & entertainment, and infrastructure/industrial real estate
- Geographic Focus
- India
- Location
- New Delhi, India (Commercial Plaza, Mahipalpur, National Highway 8)
Background
Anurag Kumar is the Chief Financial Officer of Jacob Ballas Capital India Private Limited, a New Delhi–based private equity advisory firm founded in 1995. As CFO he sits within the firm's management team alongside leaders such as Srinivas Chidambaram (Managing Director & CEO) and partner Sunil Chawla, and is responsible for the firm's finance, fund administration, and financial-control functions across the India-focused funds it advises. His firm email ([hidden]) and the New Delhi head-office line (91-11-4315-3100) are consistent across business directories and the firm's own contact details.
Jacob Ballas Capital acts as the advisor to the investment managers of three India-dedicated private equity funds with more than US$600 million under management: the New York Life International India Fund (~US$40M), the New York Life Investment Management India Fund (~US$127M), and NYLIM Jacob Ballas India Fund III (~US$440M). The firm is owned by its founding/management team together with New York Life Investment Management, which holds roughly a 25% stake. The firm describes its team of "professionals turned entrepreneurs" as having over 150 years of collective industry experience, including more than 80 years specifically in private equity advisory.
In a private equity firm of this structure, the CFO's mandate centers on fund-level finance, investor reporting, regulatory compliance for the NBFC, valuation oversight, and the financial governance of portfolio transactions and exits — rather than on sourcing deals. Public records consistently list Anurag Kumar's single, current senior role as CFO at Jacob Ballas; detailed prior-career and education specifics are not reliably documented in public sources and are therefore not asserted here.
Investment Thesis & Focus
- Growth-stage, not seed/angel: The firm provides growth capital to established Indian companies — typical tickets of roughly US$10–50 million, an investment horizon of about 3–5 years, and exits via strategic sale or IPO.
- Diversified, India-only mandate: Investments span healthcare and diagnostics, financial services and fintech, consumer/retail, media & entertainment, payments, and industrial/real-estate infrastructure.
- Long-cycle institutional capital: As advisor to closed-end New York Life–backed funds, the firm backs companies it can support through a multi-year value-creation cycle and an eventual liquidity event.
- CFO's role in the thesis: Anurag Kumar's contribution is on the financial-diligence, structuring, fund-administration, and exit-execution side rather than as a deal-originating partner — relevant context for how a founder would actually engage the firm.
Notable Investments
- Super Religare Laboratories (SRL) / Agilus Diagnostics — Diagnostics chain; Jacob Ballas India Fund and the IFC together invested ~Rs 370 crore (~US$66M); the diagnostics business later operated as Agilus Diagnostics.
- Religare Finvest — ~Rs 200 crore investment into Religare Enterprises' NBFC arm; the firm recorded an exit from Religare Enterprises on 20-Feb-2025.
- FSS (Financial Software & Systems) — Chennai-based payments processor (investment ~2014); investors including Jacob Ballas explored exits around 2024.
- Imagicaa — Mumbai-area theme-park/entertainment operator (investment ~2014).
- Inventia Healthcare — Pharmaceutical formulations company; exited around 2018–19 (around the time of an IPO filing).
- Crocodile menswear — Consumer/apparel holding; exit realized ~2018–19.
- Centrum Capital (forex business) — Investment ~2017 alongside New York Life Investments.
- Lifeline Laboratory / CBIG Consulting — Healthcare diagnostics and IT-consulting portfolio names cited in deal databases.
- Cerestra industrial real-estate fund — June 2019 partnership to establish an industrial/warehousing real-estate vehicle.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.